Cureus

The Cureus Journal of Medical ScienceAngiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-AnalysisType 2 diabetes mellitus (T2DM) increases the risk of cardiovascular morbidity and end-stage renal disease. Renin-angiotensin-aldosterone….1 day ago

News Source0130 views

The Cureus Journal of Medical ScienceAngiotensin-Converting Enzyme Inhibitors Versus Angiotensin Receptor Blockers for Cardiovascular and Renal Protection in Type 2 Diabetes: A Systematic Review and Meta-AnalysisType 2 diabetes mellitus (T2DM)…

Read more

The Cureus Journal of Medical ScienceSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a transformative therapy in type 2 diabetes mellitus (T2DM),….18 hours ago

News Source0196 views

The Cureus Journal of Medical ScienceSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Risk of Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsSodium-glucose cotransporter-2 (SGLT2)…

Read more

The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2 diabetes (T2DM) management increasingly focuses on cardiometabolic protection. Sodium-glucose co-transporter-2 inhibitors (SGLT2is)….1 day ago

News Source0205 views

The Cureus Journal of Medical ScienceCardiometabolic Benefits and Risks of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitor and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic ReviewType 2…

Read more